XM does not provide services to residents of the United States of America.
R
R

Roche


News

Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial Updates ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN
A
R

Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial

BUZZ-Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN has colo
A
R

European shares fall on French election uncertainty; log weekly gain

UPDATE 2-European shares fall on French election uncertainty; log weekly gain For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 down 0.2%, eyes on French election UK midcaps close at one-month high Aixtron rallies on strong orders Updated at 1600 GMT By Shristi Achar A, Sruthi Shankar and Jesus Calero July 5 (Reuters) - European shares fell on Friday, weighed down by losses in banks and energy stocks as investors became more caut
A
R
A
E
F
U
G

Roche Says FDA Approves Genentech’S Vabysmo Prefilled Syringe (Pfs)

BRIEF-Roche Says FDA Approves Genentech’S Vabysmo Prefilled Syringe (Pfs) July 5 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES GENENTECH’S VABYSMO PREFILLED SYRINGE (PFS) FOR THREE LEADING CAUSES OF VISION LOSS DESIGNED TO SIMPLIFY ADMINISTRATION, VABYSMO PFS PROVIDES RETINA SPECIALISTS A READY-TO-USE OPTIO VABYSMO PFS IS FIRST AND ONLY SYR
R

Roche Holding seen down on plan to halt lung cancer drug trial

BUZZ-Roche Holding seen down on plan to halt lung cancer drug trial ** Shares of Swiss drugmaker Roche Holding ROG.S seen down 2.3% in Julius Baer pre-market trade following its plans to halt trial for lung cancer treatment after 'disappointing' results ** The company said its antibody drug tiragolumab (anti-TIGIT) in combination with its Tecentriq
R
J

Roche to halt trial in latest setback for lung cancer immunotherapy

UPDATE 2-Roche to halt trial in latest setback for lung cancer immunotherapy Rewrites throughout, adds shares in paragraph 4 By Rachel More and Ludwig Burger BERLIN, July 4 (Reuters) - Roche ROG.S will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co MRK.N , casting further doubt on the drug candidate pioneered by the Swiss company.
R
J

Roche to halt trial for lung cancer treatment after 'disappointing' results

Roche to halt trial for lung cancer treatment after 'disappointing' results BERLIN, July 4 (Reuters) - Roche ROG.S intends to halt a trial for combined lung cancer treatment using a new immunotherapy called tiragolumab after results fell short of efficacy targets, the Swiss drugmaker said on Thursday. The trial, dubbed SKYSCRAPER-06, evaluates tiragolumab plus Roche's established drug Tecentriq and chemotherapy.
R

Roche Halts Trial Of Skyscraper-06 Study Due To Reduced Efficacy

BRIEF-Roche Halts Trial Of Skyscraper-06 Study Due To Reduced Efficacy July 4 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE PROVIDES UPDATE ON PHASE II/III SKYSCRAPER-06 STUDY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER SKYSCRAPER-06 EVALUATING TIRAGOLUMAB PLUS TECENTRIQ AND CHEMOTHERAPY DID NOT MEET PRIMARY ENDPOINTS OF PROGRESSION-FREE SUR
R

Swiss stocks - Factors to watch on July 4

Swiss stocks - Factors to watch on July 4 ZURICH/GDANSK, July 4 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: UBS AG UBSG.S U.S. bank State Street STT.N has won a mandate to act as custodian bank for a multibillion-dollar compensation fund of the Swiss federal government that was previously at UBS, authorities said on Wednesday.
A
R
U
S

Roche sues Stanford University, cancer-detection startup over trade secrets

UPDATE 1-Roche sues Stanford University, cancer-detection startup over trade secrets Updates July 2 story to add response from Foresight in paragraph 3 By Blake Brittain July 2 (Reuters) - Roche ROG.S has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products.
R

Swiss stocks - Factors to watch on July 3

Swiss stocks - Factors to watch on July 3 July 3 - Here are some of the main factors that may affect Swiss stocks on Wednesday: Roche ROG.S Roche has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products COMPANY STATEMENTS Dormakaba DOKA.S - says René Peter appointed CFO ad interim ANALYSTS' VIEWS VAT GROUP AG VACN.S - JEFFERIES RAIS
R

Roche sues Stanford University, cancer-detection startup over trade secrets

Roche sues Stanford University, cancer-detection startup over trade secrets By Blake Brittain July 2 (Reuters) - Roche ROG.S has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products. Roche said in the complaint filed on Monday that Stanford University professors Maximilian Diehn and Ash Alizadeh, whose technology Roche acquired in 20
R

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S

Swiss stocks - Factors to watch on July 2

Swiss stocks - Factors to watch on July 2 ZURICH/GDANSK, July 2 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: GIVAUDAN SA GIVN.S The company completed the acquisition of B.Kolormakeup & Skincare. LOGITECH INTERNATIONAL SA LOGN.S A chairperson informed the management board of the 2025 transition plan . PSP SWISS PROPERTY AG PSPN.S The company acquired a commercial property in Geneva for 58 million Swiss francs.
G
L
R
P

Financials lift Japanese shares on rate-hike speculation

Financials lift Japanese shares on rate-hike speculation By Brigid Riley TOKYO, July 2 (Reuters) - Japan's Nikkei share average rose on Tuesday, buoyed by financial sector stocks climbing on speculation that the Bank of Japan (BOJ) might raise interest rates again in the near future amid a weakening yen. The Nikkei .N225 was up 0.38% at 39,780.58 by the midday break.
R
U
J

Roche's Vabysmo Receives Positive Opinion For Extension Of Marketing Authorisation

BRIEF-Roche's Vabysmo Receives Positive Opinion For Extension Of Marketing Authorisation June 28 (Reuters) - ROCHE HOLDING AG ROG.S : EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION FOR EXTENSION OF VABYSMO® (FARICIMAB) POSITIVE OPINION FOR EXTENSION OF VABYSMO® (FARICIMAB) MARKETIN
R

Roche: CHMP Recommends EU Approval Of Roche's PiaSky For People With PNH

BRIEF-Roche: CHMP Recommends EU Approval Of Roche's PiaSky For People With PNH June 28 (Reuters) - ROCHE HOLDING AG ROG.S : CHMP RECOMMENDS EU APPROVAL OF ROCHE’S PIASKY FOR PEOPLE WITH PNH, A RARE, LIFE-THREATENING BLOOD CONDITION Source text for Eikon: ID:nGNE3NdDFn Further company coverage: ROG.S (Gdansk Newsroom)
R

EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older

BRIEF-EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older June 28 (Reuters) - Moderna Inc MRNA.O : EMA SAYS CHMP GRANTING A MARKETING AUTHORISATION FOR BALVERSA EMA: MRESVIA RSV MRNA VACCINE RECEIVED A POSITIVE OPINION FROM THE CHMP FOR PREVENTION IN ADULTS 60 YEARS OF AGE AND OLDER EMA: CHMP
P
R

Roche receives two new WHO prequalification designations, including HPV self-collection

BRIEF-Roche receives two new WHO prequalification designations, including HPV self-collection June 27 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE EXPANDS ACCESS TO CERVICAL CANCER SCREENING TOOLS WITH TWO NEW WHO PREQUALIFICATION DESIGNATIONS, INCLUDING HPV SELF-COLLECTION WORLD HEALTH ORGANIZATION (WHO) HAS AWARDED COBAS® HPV TEST PREQUALIFICATION
R

Roche's Ocrevus Subcutaneous Administration Approved By EU Commission

BRIEF-Roche's Ocrevus Subcutaneous Administration Approved By EU Commission June 25 (Reuters) - Roche Holding AG ROG.S : ROCHE’S OCREVUS SUBCUTANEOUS ADMINISTRATION APPROVED BY EUROPEAN COMMISSION, AS FIRST AND ONLY TWICE-A-YEAR INJECTION FOR RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS WORKING CLOSELY WITH NATIONAL HEALTH SYSTEMS IN EURO
R



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.